Biotech News
Related news
AVIRAtea2026-05-27 11:00 EST
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
AVIRAtea2026-09-08 11:00 EST
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
ASMBAssembly Biosciences2026-05-13 06:00 EST
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
IMNNImunon2026-09-09 12:30 EST
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
ENTAEnanta Pharmaceuticals2026-06-23 09:10 EST
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
IMNNImunon2026-03-31 12:00 EST
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
MBRXMoleculin Biotech, Inc.2026-05-21 21:02 EST
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
ASMBAssembly Biosciences2026-09-10 20:15 EST
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
SPROSpero Therapeutics2026-09-02 21:01 EST
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Atea
Oral Antiviral Therapeutics Atea Pharmaceuticals develops oral antiviral therapies for serious viral diseases. Its pipeline is built around nucleotide and nucleoside analog chemistry and combination treatment strategies. Bemnifosbuvir and Ruzasvir The lead regimen combines the nucleotide polymerase inhibitor bemnifosbuvir with the NS5A...
Recent company news
AVIRAtea2026-09-08 11:00 EST
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
AVIRAtea2026-08-12 20:05 EST
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
AVIRAtea2026-08-05 11:00 EST
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
AVIRAtea2026-07-28 11:00 EST
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
AVIRAtea2026-07-14 11:00 EST
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Stock data
- Close
- 5.26 USD
- Market cap
- 341.72M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States